<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
X Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
- - Act of 1934.
For the quarterly period ended June 30, 1998
OR
__ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.
For the transition period from _______to_______
Commission file number: 0-12128
MATRITECH, INC.
---------------
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 04-2985132
-------- ----------
(State or Other (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation or
Organization)
330 NEVADA STREET, NEWTON, MASSACHUSETTS 02460
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 928-0820
--------------
(Registrant's Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
--- ---
As of August 4, 1998 there were 18,616,602 shares of Common Stock
outstanding.
Page 1 of 17
The Exhibit Index is located on Page 17.
<PAGE>
MATRITECH, INC.
INDEX
PART I FINANCIAL INFORMATION
Page
----
ITEM 1. FINANCIAL STATEMENTS
Balance Sheets as of December 31, 1997
and June 30, 1998 3
Statements of Operations for the three and six-month periods ended
June 30, 1997 and 1998 5
Statements of Cash Flows for the six-month periods ended
June 30, 1997 and 1998 6
Notes to Financial Statements 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS 9
PART II OTHER INFORMATION
ITEM 4. SUBMISSON OF MATTERS TO A VOTE OF SECURITY HOLDERS 14
ITEM 5. OTHER INFORMATION 14
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K 15
SIGNATURES 16
Page 2 of 17
<PAGE>
PART I. - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
--------------------
MATRITECH, INC.
BALANCE SHEETS
ASSETS
<TABLE>
<CAPTION>
DECEMBER 31, JUNE 30,
1997 1998
---- ----
(Unaudited)
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $11,067,414 $7,273,171
Accounts receivable 101,941 202,722
Inventories 487,360 397,834
Prepaid expenses 127,156 97,781
----------- ----------
Total current assets 11,783,871 7,971,508
----------- ----------
PROPERTY AND EQUIPMENT, at cost:
Laboratory equipment 1,370,929 1,394,653
Office equipment 203,214 208,810
Laboratory furniture 62,739 62,739
Leasehold improvements 56,981 56,981
----------- ----------
1,693,863 1,723,183
Less-Accumulated depreciation
and amortization 872,706 969,475
----------- ----------
821,157 753,708
----------- ----------
OTHER ASSETS, net 86,745 68,452
----------- ----------
$12,691,773 $8,793,668
=========== ==========
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
Page 3 of 17
<PAGE>
MATRITECH, INC.
BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
DECEMBER 31, JUNE 30,
1997 1998
---- ----
(Unaudited)
<S> <C> <C>
CURRENT LIABILITIES:
Current maturities of note payable $ 60,733 $ 64,392
Accounts payable 378,700 272,171
Accrued expenses 354,904 499,825
------------ ------------
Total current liabilities 794,337 836,388
------------ ------------
NOTE PAYABLE, LESS CURRENT MATURITIES 208,762 175,624
------------ ------------
STOCKHOLDERS' EQUITY:
Preferred stock, $1.00 par value -
Authorized - 4,000,000 shares
Issued and outstanding - none --- ---
Common stock, $.01 par value -
Authorized -- 40,000,000 shares
Issued and outstanding -- 18,566,737
shares at December 31, 1997, and
18,608,867 shares at June 30, 1998 185,667 186,088
Additional paid-in capital 45,118,499 45,334,714
Accumulated deficit (33,615,492) (37,739,146)
------------ ------------
Total stockholders' equity 11,688,674 7,781,656
------------ ------------
$ 12,691,773 $ 8,793,668
============ ============
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
Page 4 of 17
<PAGE>
MATRITECH, INC.
STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
1997 1998 1997 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
REVENUES:
Product sales, collaborative
research and development revenue
and license fees $ 151,403 $ 269,008 $ 376,578 $ 533,503
Interest and other income 102,970 128,017 186,753 274,477
----------- ----------- ----------- -----------
254,373 397,025 563,331 807,980
----------- ----------- ----------- -----------
EXPENSES:
Research and
development 965,878 1,114,608 1,862,269 2,154,563
Selling, general and
administrative 1,375,678 1,345,411 2,310,844 2,776,866
----------- ----------- ----------- -----------
2,341,556 2,460,019 4,173,113 4,931,429
----------- ----------- ----------- -----------
Net Loss $(2,087,183) $(2,062,994) $(3,609,782) $(4,123,449)
=========== =========== =========== ===========
BASIC/DILUTED LOSS PER SHARE $ (.12) $ (.11) $ (.22) $ (.22)
=========== =========== =========== ===========
BASIC/DILUTED WEIGHTED AVERAGE
NUMBER OF
COMMON
SHARES
OUTSTANDING 16,899,740 18,605,554 16,470,442 18,592,468
=========== =========== =========== ===========
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
Page 5 of 17
<PAGE>
MATRITECH, INC.
STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
SIX MONTHS ENDED
JUNE 30,
1997 1998
---- ----
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss $(3,609,782) $(4,123,449)
Adjustments to reconcile net loss to
net cash used in operating activities -
Depreciation and amortization 50,184 115,062
Operating expense related to
issuance of common stock warrant 100,000 150,000
Changes in assets and liabilities -
Accounts receivable 538,126 (100,781)
Inventories (81,666) 89,526
Prepaid expenses (10,667) 29,375
Accounts payable 187,419 (106,529)
Accrued expenses 176,642 144,921
----------- -----------
Net cash used in operating
activities (2,649,744) (3,801,875)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and
equipment (249,036) (29,320)
----------- -----------
Net cash used in
investing activities (249,036) (29,320)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock
and exercise of common stock options 10,954,958 66,431
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
Page 6 of 17
<PAGE>
MATRITECH, INC.
STATEMENTS OF CASH FLOWS (continued)
(UNAUDITED)
<TABLE>
<CAPTION>
SIX MONTHS ENDED
JUNE 30,
1997 1998
---- ----
<S> <C> <C>
Payments on note payable --- $ (29,479)
--------------- ---------------
Net cash provided by financing activities 10,954,958 36,952
--------------- ---------------
NET INCREASE (DECREASE) IN CASH AND
CASH EQUIVALENTS 8,056,178 (3,794,243)
CASH AND CASH EQUIVALENTS, BEGINNING
OF PERIOD 6,770,336 11,067,414
--------------- ---------------
CASH AND CASH EQUIVALENTS, END OF
PERIOD $ 14,826,514 $ 7,273,171
=============== ===============
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:
Cash paid during the period for interest $ - $ 15,127
=============== ===============
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS.
Page 7 of 17
<PAGE>
MATRITECH, INC.
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
1. Operations and Basis of Presentation
- ---------------------------------------
Matritech, Inc. ( the "Company") was incorporated on October 29, 1987 to
develop, produce and distribute products for the diagnosis and potential
treatment of cancer based on its proprietary nuclear matrix protein technology.
This technology was licensed to the Company by the Massachusetts Institute of
Technology ("MIT").
The Company is devoting substantially all of its efforts toward product
research and development, raising capital and marketing products. The Company
is subject to risks common to companies in similar stages of development,
including dependence on key individuals, competition from substitute products
and larger companies, the development of commercially usable products and the
need to obtain adequate additional financing necessary to fund the development
of its future products.
The financial statements included herein have been prepared by the
Company, without audit, pursuant to the rules and regulations of the Securities
and Exchange Commission ("SEC") and include, in the opinion of management, all
adjustments, consisting of normal, recurring adjustments, necessary for a fair
presentation of interim period results. Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to such rules and regulations. The results for the interim periods
presented are not necessarily indicative of results to be expected for any
future period. It is suggested that these condensed financial statements be
read in conjunction with the audited financial statements and notes thereto
included in the Company's Annual Report on Form 10-K for the year ended December
31, 1997 filed with the SEC (File No. 0-12128).
2. Cash Equivalents
- -------------------
Cash equivalents are short-term, highly liquid investments with original
maturities of less than three months. The Company's cash equivalents primarily
consisted of auction market preferred stocks, money market accounts and
repurchase agreements at December 31, 1997 and June 30, 1998. The Company
classifies its investments in accordance with Financial Accounting Standards No.
115 "Accounting for Certain Investments in Debt and Equity Securities" (SFAS No.
115).
3. Inventories
- ----------------
Inventories are stated at the lower of cost or market and consist of the
following:
<TABLE>
<CAPTION>
December 31, June 30,
1997 1998
<S> <C> <C>
Raw materials $305,241 $274,959
Work-in-process 6,634 7,193
Finished goods 175,485 115,682
____________ ___________
$487,360 $397,834
============ ===========
</TABLE>
Page 8 of 17
<PAGE>
4. Net Loss Per Common Share
- ----------------------------
In March 1997, the Financial Accounting Standards Board issued SFAS No.
128, Earnings per Share, which established new standards for calculating and
presenting earnings per share. Basic net loss per common share was computed by
dividing net loss by the weighted average number of common shares outstanding
during the year. Diluted loss per share is the same as basic loss per share as
the effects of potential common stock are antidilutive. This accounting
change had no effect on the Company's historical net loss per common share.
5. New Accounting Pronouncements
- --------------------------------
Effective January 1, 1998, the Company adopted SFAS No. 130, "Reporting
Comprehensive Income." This Statement requires that all items recognized under
accounting standards as components of comprehensive earnings be reported in an
annual financial statement. It also requires that an entity classify items of
other comprehensive earnings (e.g., foreign currency translation adjustments and
unrealized gains and losses on certain marketable securities) by their nature in
an annual financial statement. The Company's total comprehensive loss for the
three month periods ended June 30, 1998 and 1997 were the same as reported net
loss for those periods.
In April 1998, the American Institute of Certified Public Accountants
issued Statement of Position 98-5 "Reporting on the Costs of Start-Up
Activities" ("SOP 98-5"). SOP 98-5 provides guidance on the financial reporting
of start-up costs and organization costs. It requires costs of start-up
activities and organization costs to be expensed as incurred. The Company does
not believe that the impact of SOP 98-5 will have a material impact on its
financial statements.
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
-----------------------------------------------------------------------
OF OPERATIONS
-------------
The Company was incorporated in 1987 to develop, manufacture and market
innovative cancer diagnostic products based on its proprietary NMP technology.
Matritech has been unprofitable since inception and expects to incur significant
operating losses for at least the next several years. For the period from
inception to June 30, 1998, the Company incurred a cumulative net loss of
approximately $38 million.
In the United States, the Company sells its NMP22/(R)/ Test Kit through
its own direct sales force, and in March 1998 entered into a distribution
agreement with Curtin Matheson Scientific, a division of Fisher Scientific
Company, L.L.C. ("CMS") granting CMS the right, co-exclusive with Matritech, to
distribute the NMP22 Test Kit to hospitals and commercial laboratories within
the United States. Outside the United States, the Company sells the NMP22 Test
Kit through distributors.
Page 9 of 17
<PAGE>
RESULTS OF OPERATIONS
- ---------------------
THREE MONTHS ENDED JUNE 30, 1998 COMPARED WITH THREE MONTHS ENDED JUNE 30, 1997
- -------------------------------------------------------------------------------
Product sales, collaborative research and development revenue and license
fees increased to $269,000 for the quarter ended June 30, 1998 from $151,000 for
the quarter ended June 30, 1997. Revenue from product sales increased to
$252,000 for the quarter ended June 30, 1998 as compared to $151,000 for the
second quarter of 1997 due to increased sales of the NMP22/(R)/ Test Kit in the
United States. During the second quarter of 1998 the Company recorded $17,000 in
SBIR funding for the Company's NuMA tumor marker project.
Interest and other income was $128,000 for the quarter ended June 30,
1998 and $103,000 for the quarter ended June 30, 1997. The increase was due to
higher average cash balances available for investment and higher interest rates
in the second quarter of 1998 as compared to the second quarter of 1997.
Research and development expenses increased to $1,115,000 for the quarter
ended June 30, 1998 from $966,000 for the quarter ended June 30, 1997. The
increase is primarily related to (i) increased costs associated with product
development personnel, reagents and supplies for the Company's colon and
cervical cancer projects and (ii) increased staffing of clinical affairs
personnel to manage the Company's colon cancer FDA submissions and the NMP22
screening trial and its related site management costs including travel to the
clinical sites.
Selling, general and administrative expenses decreased slightly to
$1,345,000 for the quarter ended June 30, 1998 from $1,376,000 for the quarter
ended June 30, 1997. This decrease was due to a reduction in public relations
expenses. In April 1997, the Company issued a warrant to a public relations
consultant. The Company expensed the value of the warrant, $500,000, ratably
over the one year term of its agreement with such consultant. The Company
expensed $100,000 and $37,500 of the value of this warrant during the quarters
ended June 30, 1997 and 1998, respectively.
The Company incurred a net loss of $2,063,000 for the quarter ended June
30, 1998, as compared to a net loss of $2,087,000 for the quarter ended June 30,
1997. The decrease in net loss was primarily due to an increase in product
revenue partially offset by an increase in research and development expenses.
SIX MONTHS ENDED JUNE 30, 1998 COMPARED WITH SIX MONTHS ENDED JUNE 30, 1997
- ---------------------------------------------------------------------------
Product sales, collaborative research and development revenue and license
fees increased to $534,000 for the six months ended June 30, 1998 from $377,000
for the six months ended June 30, 1997. Revenue from product sales increased to
$461,000 for the six months ended June 30, 1998 as compared to $317,000 for the
first two quarters of 1997 due to increased sales of the NMP22/(R)/ Test Kit.
During the first two quarters of 1997 the Company recorded $60,000 in milestone
revenue related to a funded development agreement with Bayer Corporation
("Bayer") which was terminated in March 1998 and during the first two quarters
of 1998 recorded $73,000 in SBIR funding for the Company's NuMA tumor marker
project.
Interest and other income was $274,000 for the six months ended June 30,
1998 and $187,000 for the six months ended June 30, 1997. The increase was due
to higher average cash balances available for investment and higher interest
rates in the first two quarters of 1998 as compared to the first two quarters of
1997.
Page 10 of 16
<PAGE>
Research and development expenses increased to $2,155,000 for the six
months ended June 30, 1998 from $1,862,000 for the six months ended June 30,
1997. The increase is primarily related to (i) increased costs associated with
product development personnel, reagents and supplies for the Company's colon and
cervical cancer projects and (ii) increased staffing of clinical affairs
personnel to manage the Company's colon cancer FDA submission and the NMP22
screening trial and its related site management costs including travel to the
clinical sites.
Selling, general and administrative expenses increased to $2,777,000 for
the six months ended June 30, 1998 from $2,311,000 for the six months ended June
30, 1997. The increase was primarily due to increased advertising agency fees
and to a lesser extent, marketing personnel costs in both the U. S. and Europe.
In April 1997, the Company issued a warrant to a public relations consultant.
The Company expensed the value of the warrant, $500,000, ratably over the one
year term of its agreement with such consultant. The Company expensed $100,000
and $150,000 of the value of this warrant during the six months ended June 30,
1997 and 1998, respectively. The balance of the increase relates to professional
fees for investor and media relations and Nasdaq National Market fees.
The Company incurred a net loss of $4,123,000 for the six months ended
June 30, 1998, as compared to a net loss of $3,610,000 for the six months ended
June 30, 1997. The increased loss was primarily the result of increased
marketing expenses for the NMP22 Test Kit, professional fees, and to a lesser
extent increased product development costs associated with the colon and
cervical cancer projects and clinical affairs.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
Since its inception, the Company has financed its operations primarily
through private and public offerings of its securities and through funded
development and marketing agreements. At December 31, 1997 and June 30, 1998,
the Company had cash and cash equivalents of $11,067,000 and $7,273,000
respectively, and working capital of $10,990,000 and $7,135,000, respectively.
The Company's primary cash infusion in 1997 was from the private sale of common
stock which totaled $10,904,000.
The Company's operating activities used cash of approximately $2,650,000
and $3,802,000 for the six-month periods ended June 30, 1997 and 1998,
respectively, primarily to fund the Company's operating loss.
The Company's investing activities used cash of approximately $249,000
and $29,000 in the six-month periods ended June 30, 1997 and 1998, respectively,
for the purchase of computer systems and office and laboratory equipment. The
Company currently estimates that it will acquire approximately $56,000 of
capital equipment during the remainder of fiscal 1998, consisting primarily of
laboratory equipment and computer hardware.
Financing activities provided cash of approximately $10,955,000 in the
six-month period ended June 30, 1997, from the private sale of common stock and
the exercise of common stock options. Financing activities provided cash of
approximately $37,000 in the six-month period ended June 30, 1998, primarily
from the exercise of stock options net of equipment loan payments.
In August 1997, the Company entered into an equipment line of credit
with Phoenix Leasing, Incorporated under which it can borrow up to $1,200,000
for equipment purchases. The equipment line of credit converts into a 48 month
term note payable. The equipment line of credit and note bear interest at
11.75% and are secured by the underlying equipment. At June 30, 1998, the
Company had approximately $950,000 available under the equipment line of credit
and had converted approximately $250,000 into a term note payable.
Page 11 of 16
<PAGE>
The Company expects to incur continued research and development expenses
and other costs, including costs related to clinical studies to commercialize
additional products based upon its NMP technology. The Company expects that
such costs will increase in the fiscal year ending December 31, 1998 and will
result in continued losses from operations. The Company will require
substantial additional funds to complete new product development, conduct
clinical trials and manufacture and market its products.
The Company's future capital requirements will depend on many factors,
including: continued scientific progress in its research and development
programs; the magnitude of its research and development programs; progress with
clinical trials for its diagnostic products; the magnitude of product sales;
the time involved in obtaining regulatory approvals; the costs involved in
filing, prosecuting and enforcing patent claims; competing technological and
market developments; and the ability of the Company to establish additional
product development and marketing arrangements to provide funding for research
and development and to conduct clinical trials, obtain regulatory approvals, and
manufacture and market certain of the Company's products.
The Company is actively seeking additional long-term funding for its
operations from various sources including collaborative arrangements and
additional public or private financings. The Company anticipates that its
existing capital resources including working capital and interest thereon will
satisfy its capital needs through 1998. The foregoing forward-looking statement
is subject to uncertainties and there can be no assurance that the Company's
needs may not change. See "Factors that may Affect Future Results-Access to
Capital." The survival of the Company in the long term, however, is dependent
on its ability to generate revenue from sales of its products. There can be no
assurance that such additional funding will be available on terms acceptable to
the Company, if at all, or that in the long term, the Company will be able to
generate sufficient revenue to achieve and maintain profitability.
FACTORS THAT MAY AFFECT FUTURE RESULTS.
The Company's future financial and operational results are subject to a
number of material risks and uncertainties that may affect such results or
conditions, including:
History of Operating Losses and Anticipated Future Losses. The Company
has incurred operating losses since its inception and expects to incur
significant operating losses for at least the next several years. While the
Company expects to improve operating results in future periods, there can be no
assurance that the Company will achieve or maintain profitability or that its
revenue will grow in the future.
Fluctuation in Operating Results. The Company's future operating results
may vary significantly from quarter to quarter or from year to year depending on
a number of factors including: the timing and size of orders from the Company's
customers and distributors; the timing of payments from corporate partners and
research grants; regulatory approvals and the introduction of new products by
the Company; and the market acceptance of the Company's products. The Company's
current planned expense levels are based in part upon expectations as to future
revenue. Consequently, profits may vary significantly from quarter to quarter
or year to year based on the timing of revenue. Revenue or profits in any
period will not necessarily be indicative of results in subsequent periods.
Uncertainties Associated with Future Performance. The Company's success
in the market for diagnostic products will depend, in part, on the Company's
ability to: successfully develop, test, produce and market its products; obtain
necessary governmental approvals in a timely manner; attract and maintain key
employees; and successfully respond to technological changes in its marketplace.
The Company's success in markets outside the United States is dependent on the
performance of independent distributors over which the Company has limited
control.
Page 12 of 17
<PAGE>
Near-Term Dependence Upon NMP22. The Company anticipates that in the
near-term it will be substantially dependent on the success of the NMP22/(R)/
Test Kit, which was approved for sale in the U.S. by the FDA in 1996 and
approved for sale in Japan in 1998 and expects to generate substantially all of
its near-term product sales from the sale of NMP22 Test Kits. The Company would
experience a material adverse effect on its business, financial condition and
results of operations if the NMP22 Test Kit does not achieve wide market
acceptance. The remainder of the Company's products are awaiting FDA approval or
are in development and there can be no assurance that it will be successful with
such regulatory approvals and product development.
Access to Capital. The Company is currently seeking to raise additional
capital and will consider from time to time various financing alternatives,
including equity or debt financings and corporate partnering arrangements.
There can be no assurance, however, that this funding will be available on terms
acceptable to the Company, if at all. If additional financing is not available,
the Company may be required to curtail expenses or take other steps that
adversely affect the Company's future performance.
Year 2000 Compliance. Certain of the Company's internal computer systems
are not Year 2000 compliant. Matritech has examined this problem and expects to
implement successfully the systems and programming changes necessary to address
Year 2000 issues and does not believe the cost of such actions will have a
material effect on the Company's results of operations or financial condition.
There can be no assurances, however, that there will not be a delay in, or
increased costs associated with, the implementation of such changes, and the
Company's inability to implement such changes could have an adverse effect on
future results of operations. In addition, there can be no assurance that the
Company's customers and suppliers will not be adversely affected by their own
Year 2000 issues, which may indirectly adversely and materially affect the
Company.
Page 13 of 17
<PAGE>
PART II. - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
---------------------------------------------------
(a) The annual meeting (the "Annual Meeting") of stockholders of
Matritech was held on June 19, 1998.
(b) The following directors were elected at the Annual Meeting:
Votes
Election of Directors For Withheld
---------- --------
J. Robert Buchanan 16,298,198 92,873
Stephen D. Chubb 16,283,848 107,223
David L. Corbet 16,301,298 89,773
Thomas R. Morse 16,300,898 90,173
David Rubinfien 16,299,898 91,173
T. Stephen Thompson 16,301,298 89,773
C. William Zadel 16,298,798 92,273
(c) The following other matter was proposed and voted upon as
indicated:
To ratify the selection of the firm of Arthur Andersen LLP as
auditors for the fiscal year ending December 31, 1998. With
16,302,630 voting for, 63,861 shares against, and 24,580
abstaining, the proposal was passed.
ITEM 5. OTHER INFORMATION
-----------------
Proposals of stockholders intended for inclusion in the Proxy
Statement to be furnished to all stockholders entitled to vote at
the 1999 Annual Meeting of Stockholders pursuant to SEC Rule 14a-8
must be received at the Company's principal executive offices not
later than December 30, 1998. The deadline for providing timely
notice to the Company of matters that stockholders otherwise
desire to introduce at the 1999 Annual Meeting of Stockholders is
March 30, 1999. In order to curtail controversy as to the date
upon which such written notice is received by the Company, it is
suggested that such notice be submitted by Certified Mail, Return
Receipt Requested.
Page 14 of 17
<PAGE>
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
--------------------------------
(a) Exhibits:
--------
27 Financial Data Schedule
(b) Reports on Form 8-K:
On May 20, 1998 the Company filed a Current Report on Form 8-K
dated as of May 14, 1998 including Item 5.
Item 5 reported the following events:
(i) Matritech, Inc. (the "Company") received a determination from
the U.S. Food and Drug Administration ("FDA") that its
NuMA/(TM)/ Test Kit for colon cancer did not meet the
criteria for 510(k) marketing clearance.
(ii) Leslie R. Teso, Vice President, Finance, Secretary and
Treasurer would be leaving the Company.
Page 15 of 17
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MATRITECH, INC.
Date: August 13, 1998 By: /s/ Stephen D. Chubb
_______________________
Stephen D. Chubb
Chairman and Chief
Executive Officer
(principal executive
and financial officer)
Page 16 of 17
<PAGE>
EXHIBIT INDEX
Exhibit
Number Description
- ------ -----------
27 Financial Data Schedule
Page 17 of 17
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FORM
10-Q FOR THE QUARTER ENDED JUNE 30, 1998 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> JUN-30-1998
<CASH> 7,273
<SECURITIES> 0
<RECEIVABLES> 203
<ALLOWANCES> 0
<INVENTORY> 398
<CURRENT-ASSETS> 7,972
<PP&E> 1,723
<DEPRECIATION> 969
<TOTAL-ASSETS> 8,794
<CURRENT-LIABILITIES> 836
<BONDS> 0
0
0
<COMMON> 186
<OTHER-SE> 7,596
<TOTAL-LIABILITY-AND-EQUITY> 8,794
<SALES> 534
<TOTAL-REVENUES> 808
<CGS> 0
<TOTAL-COSTS> 4,931
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (4,123)
<INCOME-TAX> 0
<INCOME-CONTINUING> (4,123)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (4,123)
<EPS-PRIMARY> (0.22)
<EPS-DILUTED> (0.22)
</TABLE>
